Project: Advancing Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are site-directed drugs with great potential, but most ADCs have uncontrollable drug-antibody-ratios (DARs). In Advanco we will demonstrate how ChromaCon’s MCSGP purification technology, in combination with Alphalyse’s analytical methods, can ensure narrow DAR profiles, thereby improving safety and efficacy of ADCs. To take the DAR control even further, ChromaCon will develop a novel linker technology with controllable linker attachment sites to the antibody.

Acronym Advanco (Reference Number: 9503)
Duration 01/04/2015 - 01/04/2017
Project Topic Other Industrial Technologies
Network Eurostars 2
Call Eurostars Cut-Off 2

Project partner

Number Name Role Country
20874 ChromaCon AG Coordinator Switzerland
20875 Alphalyse A/S Partner Denmark